Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

JCO Oncology Practice
Sonia Pernas, Sara M Tolaney

Abstract

The addition of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, 15%-31% of patients still develop disease recurrence, on the basis of long-term follow-up of adjuvant pivotal trials. A better understanding of tumor biology has led to the development of optimized anti-HER2 drugs and add-on strategies to further improve survival outcomes. In the neoadjuvant setting, dual HER2 blockade with trastuzumab and pertuzumab plus chemotherapy has increased the rate of pathologic complete response, a surrogate marker of improved long-term outcome; yet, in the adjuvant setting, it has led to small benefits in invasive disease-free survival. Extended adjuvant therapy with the irreversible pan-HER2 inhibitor neratinib is an option for selected patients with HER2-positive and estrogen receptor-positive disease who have received neoadjuvant or adjuvant chemotherapy plus trastuzumab. Additionally, the use of the antibody-drug conjugate trastuzumab-emtansine has led to a significant improvement in invasive disease-free survival for patients with residual disease following neoadjuvant therapy and has taught us the importance of using preo...Continue Reading

References

Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Aug 21, 2014·Journal of the National Cancer Institute·Aleix PratJosé Baselga
Oct 22, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Edith A PerezNorman Wolmark
May 4, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D MavroudisUNKNOWN Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece
Nov 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine Piccart-GebhartEdith A Perez
Jan 31, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W Fraser SymmansGabriel N Hortobagyi
Jun 6, 2017·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN APHINITY Steering Committee and Investigators
Feb 23, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitrios ZardavasSherene Loi
Sep 17, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ConteV Guarneri
Dec 6, 2018·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN KATHERINE Investigators
Feb 6, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roisin M ConnollyVered Stearns
Feb 20, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V GuarneriP F Conte
Apr 3, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara M TolaneyEric P Winer
May 1, 2019·Journal of the National Cancer Institute·Aleix PratMothaffar F Rimawi
Jun 4, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara A HurvitzDennis Slamon
Oct 31, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mothaffar F RimawiUNKNOWN Translational Breast Cancer Research Consortium
Dec 12, 2019·The New England Journal of Medicine·Shanu ModiUNKNOWN DESTINY-Breast01 Investigators
Dec 12, 2019·The New England Journal of Medicine·Rashmi K MurthyEric P Winer
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J BursteinUNKNOWN Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Feb 15, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shanu ModiShunji Takahashi
Mar 1, 2020·Seminars in Cancer Biology·Caterina MarchiòAnna Sapino
May 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C H BarcenasUNKNOWN CONTROL Study Investigators
May 30, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy U LinEric P Winer

❮ Previous
Next ❯

Citations

Jun 11, 2021·JCO Oncology Practice·Sara A Hurvitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.